{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:56:59Z","timestamp":1764172619512,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10549-024-07308-8","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:01:56Z","timestamp":1713834116000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial"],"prefix":"10.1007","volume":"206","author":[{"given":"Saskia","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-7208","authenticated-orcid":false,"given":"Olga","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"7308_CR1","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program Cancer Stat Facts: Female Breast Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed September 9th, 2023"},{"key":"#cr-split#-7308_CR2.1","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute (2023) Apr 19. [updated: 2023"},{"key":"#cr-split#-7308_CR2.2","unstructured":"cited 2023 Sep 9]. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries"},{"key":"7308_CR3","doi-asserted-by":"publisher","first-page":"1058722","DOI":"10.3389\/fpubh.2022.1058722","volume":"10","author":"W Zhang","year":"2022","unstructured":"Zhang W, Bai Y, Sun C, Lv Z, Wang S (2022) Racial and regional disparities of triple negative breast cancer incidence rates in the United States: an analysis of 2011\u20132019 NPCR and SEER incidence data. Front Public Health 10:1058722. https:\/\/doi.org\/10.3389\/fpubh.2022.1058722","journal-title":"Front Public Health"},{"issue":"7","key":"7308_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jamaoncol.2021.1254","volume":"7","author":"B Cho","year":"2021","unstructured":"Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, Liu Y (2021) Evaluation of Racial\/Ethnic Differences in Treatment and mortality among women with triple-negative breast Cancer. JAMA Oncol 7(7):1016\u20131023. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1254","journal-title":"JAMA Oncol"},{"issue":"4","key":"7308_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/0008-5472.CAN-20-3094","volume":"81","author":"F Wang","year":"2021","unstructured":"Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO (2021) Racial\/Ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast Cancer. Cancer Res 81(4):1163\u20131170. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3094","journal-title":"Cancer Res"},{"issue":"1","key":"7308_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","volume":"36","author":"L Ellis","year":"2018","unstructured":"Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL (2018) Racial and ethnic disparities in Cancer Survival: the contribution of Tumor, Sociodemographic, Institutional, and Neighborhood characteristics. J Clin Oncol 36(1):25\u201333. https:\/\/doi.org\/10.1200\/JCO.2017.74.2049","journal-title":"J Clin Oncol"},{"issue":"1","key":"7308_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2017.73.7932","volume":"36","author":"A Jemal","year":"2018","unstructured":"Jemal A, Robbins AS, Lin CC, Flanders WD, DeSantis CE, Ward EM, Freedman RA (2018) Factors that contributed to Black-White disparities in Survival among Nonelderly Women with breast Cancer between 2004 and 2013. J Clin Oncol 36(1):14\u201324. https:\/\/doi.org\/10.1200\/JCO.2017.73.7932","journal-title":"J Clin Oncol"},{"key":"7308_CR8","doi-asserted-by":"publisher","first-page":"576964","DOI":"10.3389\/fpubh.2020.576964","volume":"8","author":"O Prakash","year":"2020","unstructured":"Prakash O, Hossain F, Danos D, Lassak A, Scribner R, Miele L (2020) Racial disparities in Triple negative breast Cancer: a review of the role of Biologic and non-biologic factors. Front Public Health 8:576964. https:\/\/doi.org\/10.3389\/fpubh.2020.576964","journal-title":"Front Public Health"},{"issue":"1","key":"7308_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1089\/heq.2021.0041","volume":"6","author":"L Eldridge","year":"2022","unstructured":"Eldridge L, Berrigan D (2022) Structural racism and triple-negative breast Cancer among Black and White women in the United States. Health Equity 6(1):116\u2013123. https:\/\/doi.org\/10.1089\/heq.2021.0041","journal-title":"Health Equity"},{"issue":"25","key":"7308_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","volume":"36","author":"KD Miller","year":"2018","unstructured":"Miller KD, O\u2019Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. (2018) Double-blind phase III trial of Adjuvant Chemotherapy with and without Bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast Cancer (E5103). J Clin Oncol 36(25):2621\u20132629. https:\/\/doi.org\/10.1200\/JCO.2018.79.2028","journal-title":"J Clin Oncol"},{"issue":"7","key":"7308_CR11","doi-asserted-by":"publisher","first-page":"e27120","DOI":"10.7759\/cureus.27120","volume":"14","author":"SS Makhani","year":"2022","unstructured":"Makhani SS, Bouz A, Stavros S, Zucker I, Tercek A, Chung-Bridges K (2022) Racial and ethnic inequality in Survival outcomes of Women with Triple negative breast Cancer. Cureus 14(7):e27120. https:\/\/doi.org\/10.7759\/cureus.27120","journal-title":"Cureus"},{"issue":"2","key":"7308_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-022-06736-8","volume":"196","author":"BA Oppong","year":"2022","unstructured":"Oppong BA, Rolle AA, Ndumele A, Li Y, Fisher JL, Bhattacharyya O, Adeyanju T, Paskett ED (2022) Are there differences in outcomes by race among women with metastatic triple-negative breast cancer? Breast Cancer Res Treat 196(2):399\u2013408. https:\/\/doi.org\/10.1007\/s10549-022-06736-8","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"7308_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2022.7835","volume":"9","author":"H Sung","year":"2023","unstructured":"Sung H, Wiese D, Jatoi I, Jemal A (2023) State variation in racial and ethnic disparities in incidence of Triple-negative breast Cancer among US women. JAMA Oncol 9(5):700\u2013704. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7835","journal-title":"JAMA Oncol"},{"issue":"5","key":"7308_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10552-022-01557-y","volume":"33","author":"EK Michaels","year":"2022","unstructured":"Michaels EK, Canchola AJ, Beyer KMM, Zhou Y, Shariff-Marco S, Gomez SL (2022) Home mortgage discrimination and incidence of triple-negative and luminal A breast cancer among non-hispanic black and non-hispanic White females in California, 2006\u20132015. Cancer Causes Control 33(5):727\u2013735. https:\/\/doi.org\/10.1007\/s10552-022-01557-y","journal-title":"Cancer Causes Control"},{"issue":"7","key":"7308_CR15","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cam4.1117","volume":"6","author":"G Vidal","year":"2017","unstructured":"Vidal G, Bursac Z, Miranda-Carboni G, White-Means S, Starlard-Davenport A (2017) Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee. Cancer Med 6(7):1776\u20131786. https:\/\/doi.org\/10.1002\/cam4.1117","journal-title":"Cancer Med"},{"issue":"7","key":"7308_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/tbj.14225","volume":"27","author":"A Lehrberg","year":"2021","unstructured":"Lehrberg A, Davis MB, Baidoun F, Petersen L, Susick L, Jenkins B, Chen Y, Ivanics T, Rakitin I, Bensenhaver J, Proctor E, Nathanson SD, Newman LA (2021) Outcome of African-American compared to White-American patients with early-stage breast cancer, stratified by phenotype. Breast J 27(7):573\u2013580. https:\/\/doi.org\/10.1111\/tbj.14225","journal-title":"Breast J"},{"issue":"2","key":"7308_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-021-06506-y","volume":"192","author":"M Sarma","year":"2022","unstructured":"Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O\u2019Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S (2022) Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. Breast Cancer Res Treat 192(2):411\u2013421. https:\/\/doi.org\/10.1007\/s10549-021-06506-y","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"7308_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40615-020-00860-1","volume":"8","author":"HR Cherng","year":"2021","unstructured":"Cherng HR, Rice SR, Hamza M, Murali S, Rosenblatt P, Tkaczuk KHR, Bellavance E, Cheston S, Amin N, Nichols E (2021) Patterns of failure in Triple negative breast Cancer patients in an Urban, Predominately Black Population. J Racial Ethn Health Disparities 8(4):1035\u20131046. https:\/\/doi.org\/10.1007\/s40615-020-00860-1","journal-title":"J Racial Ethn Health Disparities"},{"issue":"1","key":"7308_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10549-021-06158-y","volume":"188","author":"J Luo","year":"2021","unstructured":"Luo J, Kroenke CH, Hendryx M, Shadyab AH, Liu N, Chen X, Wang F, Thomas F, Saquib N, Qi L, Cheng TD, Arthur R, Wactawski-Wende J (2021) Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women. Breast Cancer Res Treat 188(1):283\u2013293. https:\/\/doi.org\/10.1007\/s10549-021-06158-y","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7308_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-020-05545-1","volume":"180","author":"E Linnenbringer","year":"2020","unstructured":"Linnenbringer E, Geronimus AT, Davis KL, Bound J, Ellis L, Gomez SL (2020) Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among black and white women. Breast Cancer Res Treat 180(2):437\u2013447. https:\/\/doi.org\/10.1007\/s10549-020-05545-1","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"7308_CR21","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1177\/000313481808400743","volume":"84","author":"L Samiian","year":"2018","unstructured":"Samiian L, Sharma P, Van Den Bruele AB, Smotherman C, Vincent M, Crandall M (2018) The effect of insurance and race on breast Cancer Tumor Biology and short-term outcomes. Am Surg 84(7):1223\u20131228","journal-title":"Am Surg"},{"key":"7308_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canep.2018.10.015","volume":"58","author":"L Zhang","year":"2019","unstructured":"Zhang L, King J, Wu XC, Hsieh MC, Chen VW, Yu Q, Fontham E, Loch M, Pollack LA, Ferguson T (2019) Racial\/ethnic differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: findings from ten National Program of Cancer registries states. Cancer Epidemiol 58:1\u20137. https:\/\/doi.org\/10.1016\/j.canep.2018.10.015","journal-title":"Cancer Epidemiol"},{"issue":"14","key":"7308_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/jnci\/djp175","volume":"101","author":"KS Albain","year":"2009","unstructured":"Albain KS, Unger JM, Crowley JJ, Coltman CA Jr., Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101(14):984\u2013992. https:\/\/doi.org\/10.1093\/jnci\/djp175","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"7308_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jnci\/djaa148","volume":"113","author":"KS Albain","year":"2021","unstructured":"Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA (2021) Race, ethnicity, and clinical outcomes in hormone Receptor-Positive, HER2-Negative, node-negative breast Cancer in the Randomized TAILORx Trial. J Natl Cancer Inst 113(4):390\u2013399. https:\/\/doi.org\/10.1093\/jnci\/djaa148","journal-title":"J Natl Cancer Inst"},{"key":"7308_CR25","doi-asserted-by":"publisher","unstructured":"Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K (2023) Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007). Cancer Research 83 (5_Supplement): GS1-01-GS01-01. https:\/\/doi.org\/10.1158\/1538?7445.Sabcs22-gs1-01","DOI":"10.1158\/1538?7445.Sabcs22-gs1-01"},{"issue":"6","key":"7308_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamasurg.2023.0297","volume":"158","author":"O Kantor","year":"2023","unstructured":"Kantor O, King TA, Freedman RA, Mayer EL, Chavez-MacGregor M, Korde LA, Sparano JA, Mittendorf EA (2023) Racial and ethnic disparities in Locoregional recurrence among patients with hormone Receptor-Positive, node-negative breast Cancer: a Post Hoc Analysis of the TAILORx Randomized Clinical Trial. JAMA Surg 158(6):583\u2013591. https:\/\/doi.org\/10.1001\/jamasurg.2023.0297","journal-title":"JAMA Surg"},{"issue":"14","key":"7308_CR27","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/cncr.34241","volume":"128","author":"G Kim","year":"2022","unstructured":"Kim G, Pastoriza JM, Qin J, Lin J, Karagiannis GS, Condeelis JS, Yothers G, Anderson S, Julian T, Entenberg D, Rohan TE, Xue X, Sparano JA, Oktay MH (2022) Racial disparity in distant recurrence-free survival in patients with localized breast cancer: a pooled analysis of National Surgical adjuvant breast and Bowel Project trials. Cancer 128(14):2728\u20132735. https:\/\/doi.org\/10.1002\/cncr.34241","journal-title":"Cancer"},{"issue":"5","key":"7308_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/jnci\/djr543","volume":"104","author":"JA Sparano","year":"2012","unstructured":"Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr., Wood WC, Davidson NE (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104(5):406\u2013414. https:\/\/doi.org\/10.1093\/jnci\/djr543","journal-title":"J Natl Cancer Inst"},{"key":"7308_CR29","doi-asserted-by":"publisher","unstructured":"Schneider BP, Shen F, Jiang G, O\u2019Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA, Sledge GW Jr., Miller KD (2017) Impact of genetic ancestry on outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017. https:\/\/doi.org\/10.1200\/PO.17.00059","DOI":"10.1200\/PO.17.00059"},{"issue":"27","key":"7308_CR30","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1200\/JCO.2005.12.633","volume":"23","author":"D Hershman","year":"2005","unstructured":"Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, Neugut AI (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23(27):6639\u20136646. https:\/\/doi.org\/10.1200\/JCO.2005.12.633","journal-title":"J Clin Oncol"},{"issue":"4","key":"7308_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602\u2013606. https:\/\/doi.org\/10.1200\/JCO.2003.07.071","journal-title":"J Clin Oncol"},{"issue":"5","key":"7308_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djy136","volume":"111","author":"SB Wheeler","year":"2019","unstructured":"Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L, Olshan A, Tse CK, Bell ME, Weinberger M, Reeder-Hayes KE (2019) Endocrine therapy nonadherence and discontinuation in Black and White women. J Natl Cancer Inst 111(5):498\u2013508. https:\/\/doi.org\/10.1093\/jnci\/djy136","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"7308_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-017-4166-z","volume":"163","author":"GH Rauscher","year":"2017","unstructured":"Rauscher GH, Silva A, Pauls H, Frasor J, Bonini MG, Hoskins K (2017) Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Res Treat 163(2):321\u2013330. https:\/\/doi.org\/10.1007\/s10549-017-4166-z","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7308_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/carcin\/bgx037","volume":"38","author":"SK Deshmukh","year":"2017","unstructured":"Deshmukh SK, Srivastava SK, Tyagi N, Ahmad A, Singh AP, Ghadhban AAL, Dyess DL, Carter JE, Dugger K, Singh S (2017) Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings. Carcinogenesis 38(8):757\u2013765. https:\/\/doi.org\/10.1093\/carcin\/bgx037","journal-title":"Carcinogenesis"},{"issue":"11","key":"7308_CR35","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1245\/s10434-021-09688-3","volume":"28","author":"S Obeng-Gyasi","year":"2021","unstructured":"Obeng-Gyasi S, Asad S, Fisher JL, Rahurkar S, Stover DG (2021) Socioeconomic and Surgical disparities are Associated with Rapid Relapse in patients with triple-negative breast Cancer. Ann Surg Oncol 28(11):6500\u20136509. https:\/\/doi.org\/10.1245\/s10434-021-09688-3","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"7308_CR36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djaa215","volume":"113","author":"S Yao","year":"2021","unstructured":"Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, Evans S, Hong CC, Qi Q, Davis W, Liu S, Bandera EV, Odunsi K, Takabe K, Khoury T, Ambrosone CB (2021) Breast Tumor Microenvironment in Black women: a distinct signature of CD8\u2009+\u2009T-Cell exhaustion. J Natl Cancer Inst 113(8):1036\u20131043. https:\/\/doi.org\/10.1093\/jnci\/djaa215","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7308_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13058-021-01493-w","volume":"23","author":"V Yaghoobi","year":"2021","unstructured":"Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O\u2019Meara T, Fernandez AI, Pusztai L, Rimm DL (2021) Quantitative assessment of the immune microenvironment in African American Triple negative breast Cancer: a case-control study. Breast Cancer Res 23(1):113. https:\/\/doi.org\/10.1186\/s13058-021-01493-w","journal-title":"Breast Cancer Res"},{"key":"7308_CR38","doi-asserted-by":"publisher","unstructured":"Martini R, Delpe P, Chu TR, Arora K, Lord B, Verma A, Bedi D, Karanam B, Elhussin I, Chen Y, Gebregzabher E, Oppong JK, Adjei EK, Jibril Suleiman A, Awuah B, Muleta MB, Abebe E, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Chitale DA, Bensenhaver JM, Nathanson DS, Jackson L, Petersen LF, Proctor E, Stonaker B, Gyan KK, Gibbs LD, Monojlovic Z, Kittles RA, White J, Yates CC, Manne U, Gardner K, Mongan N, Cheng E, Ginter P, Hoda S, Elemento O, Robine N, Sboner A, Carpten JD, Newman L, Davis MB (2022) African Ancestry-Associated Gene expression profiles in Triple-negative breast Cancer Underlie altered Tumor Biology and clinical outcome in women of African descent. Cancer Discov 12(11):2530\u20132551. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0138","DOI":"10.1158\/2159-8290.CD-22-0138"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07308-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07308-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07308-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:13:12Z","timestamp":1718604792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07308-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7308"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07308-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ELM reports consulting roles for Lilly, AstraZeneca, and Novartis. EAM reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Exact sciences (formerly Genomic Health), Merck, Moderna, Roche\/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche\/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. She receives research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor. She also reports uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports speaker honoraria and compensated service on scientific Advisory Board of Exact Sciences. She is also a Senior Associate Editor for Breast Cancer Research and Treatment. MCM reports consulting for Exact Sciences, Pfizer, Roche, Astra Zeneca, Lilly, Novartis, and Abbott; and research support from Novartis and Pfizer. LAN reports research support from Genentech. The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Brigham and Women\u2019s Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}